美股異動 | 禮來(LLY.US)逆市漲2.45% 摩根士丹利上調其目標價
格隆匯4月6日丨禮來(LLY.US)逆市漲2.45%,報299.65美元。摩根士丹利分析師Terence Flynn表示,儘管美國製藥行業總體上處於建設性的背景下,但專利懸崖(Patent cliff)即將到來,需要對標的進行篩選。他認為能夠在2025-2030年實現增長的公司將處於最佳位置,而禮來擁有製藥行業“最強勁的新產品週期”前景,在未來兩年,公司可能推出五種新藥。他將禮來的目標價從265美元提升至364美元,同時維持買入評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.